



REMARKS/ARGUMENTS**Double Patenting**

The claims are provisionally rejected based on the judicially created double patenting doctrine over Serial Numbers 11/778,800 and 11/747,490. Applicants respectfully traverse the rejection.

The rejection is based upon the allegation that the claimed compounds are positional isomers of those claimed in the '800 and '490 applications. Applicants respectfully point out that isomers in these particular positions of prostaglandin compounds are known to have substantially different biological properties.



Prostaglandin E2



Prostaglandin D2

For example, the two prostaglandin positional isomers, prostaglandin E2 and prostaglandin D2, have dramatically different activities.¹ The compounds claimed in the present application similarly differ from the '800 and '490 applications in the position of the carbonyl group. Thus, they would be expected to have different activity and are not obvious over one another.

In light of the amendments and arguments made herein, Applicants respectfully request that the claims be allowed.

¹ See Nurumiya, et. al., *Physiological Review*, Vol 79 (1999), No. 4, 1193-1226, especially pp. 1203-1204, enclosed.

No fee is believed due in connection with this communication. However, if applicant is in error please charge Deposit Account 01-0885 for any fees related to this response.

Dated: August 12, 2008

Respectfully submitted,

/Brent A. Johnson/
Brent A. Johnson
Registration No. 51,851
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc. (T2-7H)
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714/246-4348

Enclosures:

Nurumiya, et. al., Physiological Review, Vol 79 (1999), No. 4, 1193-1226.